Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study

Macular DiseasesSurgery and Intervention

Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration

Am J Ophthalmol

Kaufmann GT, Boucher N, Sharma C, Aggarwal N, Starr MR

doi: 10.1016/j.ajo.2024.10.017

Macular Diseases

Fluid fluctuations assessed with artificial intelligence during the maintenance phase impact anti-vascular endothelial growth factor visual outcomes in a multicentre, routine clinical care national age-related macular degeneration database

Br J Ophthalmol

Martin-Pinardel R, Izquierdo-Serra J, Bernal-Morales C, De Zanet S, Garay-Aramburu G, Puzo M, Arruabarrena C, Sararols L, Abraldes M, Broc L, Escobar-Barranco JJ, Figueroa M, Zapata MA, Ruiz-Moreno JM, Parrado-Carrillo A, Moll-Udina A, Alforja S, Figueras-Roca M, Gómez-Baldó L, Ciller C, Apostolopoulos S, Mishchuk A, Casaroli-Marano RP, Zarranz-Ventura J, from the FRB SPAIN-IMAGE Project Investigators

doi: 10.1136/bjo-2024-325615

Macular Diseases

How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema

BMC Ophthalmol

Singh RP, Tabano D, Kuo BL, LaPrise A, Leng T, Kim E, Hatfield M, Garmo V

doi: 10.1186/s12886-024-03797-9

Macular Diseases

Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study

Ophthalmol Ther

Shellvarajah M, Nguyen V, Steinmann S, Gillies MC, Sagkriotis A, Barthelmes D

doi: 10.1007/s40123-025-01140-z

Macular Diseases

Acceptance of the Disease in Patients Diagnosed with Neovascular Age-Related Macular Degeneration Depending on Visual Parameters-Before and After a Series of Seven Intravitreal Injections

J Clin Med

Nowak M, Cybulska AM, Schneider-Matyka D, Grochans E, Walaszek I, Panczyk M, Nowicki GJ, Rachubińska K

doi: 10.3390/jcm14020447

Macular Diseases

Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

J Clin Med

Hatz K, Ambresin A, Schmid M, Prünte C, Barthelmes D, Machewitz T, Allmeier H, Somfai GM, XTEND Study Group

doi: 10.3390/jcm14072370

Macular Diseases

Ten-Year Incidence, Risk Factors and Progression Rate of Macular Atrophy in Neovascular Age-Related Macular Degeneration

Clin Exp Ophthalmol

Romano F, Casaluci M, Valastro A, Airaldi M, Milella P, Pozzo Giuffrida F, Cozzi E, Aretti A, Teo KY, Cheung CMG, Nassisi M, Viola F, Staurenghi G, Invernizzi A

doi: 10.1111/ceo.14608

Macular Diseases

Adherence to intravitreal aflibercept in neovascular age-related macular degeneration: 24-month results from the ANDROMEDA study

Ophthalmol Retina

Holz FG, Ziemssen F, Bauer Steinhusen U, Wachtlin J, Schürks M, Lorenz K, Scholz P, Machewitz T, Rech C, Lanzl I, Lommatzsch A, Finger RP, ANDROMEDA Study Group

doi: 10.1016/j.oret.2025.09.004

Macular Diseases

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series

BMC Ophthalmol

Bantounou MA, Elsheikh M, Ijasan A, Santiago C

doi: 10.1186/s12886-025-03953-9

Related content

Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration

Fluid fluctuations assessed with artificial intelligence during the maintenance phase impact anti-vascular endothelial growth factor visual outcomes in a multicentre, routine clinical care national age-related macular degeneration database

How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema

Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study

Acceptance of the Disease in Patients Diagnosed with Neovascular Age-Related Macular Degeneration Depending on Visual Parameters-Before and After a Series of Seven Intravitreal Injections

Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

Ten-Year Incidence, Risk Factors and Progression Rate of Macular Atrophy in Neovascular Age-Related Macular Degeneration

Adherence to intravitreal aflibercept in neovascular age-related macular degeneration: 24-month results from the ANDROMEDA study

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series